Iovance Raises 2026 Revenue Guidance to $410—$420M on Strong Amtagvi, Proleukin Demand

Iovance raised full year 2026 revenue guidance to $410 to $420 million, driven by strong U.S. demand for Amtagvi and Proleukin.Key Highlights:Original SEC Filing: IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ] - 8-K - Sep. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifyi…